208 related articles for article (PubMed ID: 19366661)
1. Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential.
Li LZ; Zhou R; Xu HN; Moon L; Zhong T; Kim EJ; Qiao H; Reddy R; Leeper D; Chance B; Glickson JD
Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6608-13. PubMed ID: 19366661
[TBL] [Abstract][Full Text] [Related]
2. Predicting melanoma metastatic potential by optical and magnetic resonance imaging.
Li LZ; Zhou R; Zhong T; Moon L; Kim EJ; Qiao H; Pickup S; Hendrix MJ; Leeper D; Chance B; Glickson JD
Adv Exp Med Biol; 2007; 599():67-78. PubMed ID: 17727249
[TBL] [Abstract][Full Text] [Related]
3. ³¹P-MRS studies of melanoma xenografts with different metastatic potential.
Li LZ; Zhou R; Leeper DB; Glickson JD
Adv Exp Med Biol; 2011; 701():69-73. PubMed ID: 21445771
[TBL] [Abstract][Full Text] [Related]
4. Characterizing breast cancer mouse xenografts with T₁ρ -MRI: a preliminary study.
Li LZ; Xu HN; Reddy R
Adv Exp Med Biol; 2011; 701():137-42. PubMed ID: 21445780
[TBL] [Abstract][Full Text] [Related]
5. Quantitative mitochondrial redox imaging of breast cancer metastatic potential.
Xu HN; Nioka S; Glickson JD; Chance B; Li LZ
J Biomed Opt; 2010; 15(3):036010. PubMed ID: 20615012
[TBL] [Abstract][Full Text] [Related]
6. Histological basis of MR/optical imaging of human melanoma mouse xenografts spanning a range of metastatic potentials.
Xu HN; Zhou R; Nioka S; Chance B; Glickson JD; Li LZ
Adv Exp Med Biol; 2009; 645():247-53. PubMed ID: 19227478
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line.
Welch DR; Bisi JE; Miller BE; Conaway D; Seftor EA; Yohem KH; Gilmore LB; Seftor RE; Nakajima M; Hendrix MJ
Int J Cancer; 1991 Jan; 47(2):227-37. PubMed ID: 1671030
[TBL] [Abstract][Full Text] [Related]
8. Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential.
Hendrix MJ; Seftor EA; Chu YW; Seftor RE; Nagle RB; McDaniel KM; Leong SP; Yohem KH; Leibovitz AM; Meyskens FL
J Natl Cancer Inst; 1992 Feb; 84(3):165-74. PubMed ID: 1371813
[TBL] [Abstract][Full Text] [Related]
9. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of tumors: a preclinical study of cervical carcinoma and melanoma xenografts.
Øvrebø KM; Ellingsen C; Hompland T; Rofstad EK
Acta Oncol; 2013 Apr; 52(3):604-11. PubMed ID: 22671573
[TBL] [Abstract][Full Text] [Related]
10. Distinct regulation of pHin and [Ca2+]in in human melanoma cells with different metastatic potential.
Martínez-Zaguilán R; Martinez GM; Gomez A; Hendrix MJ; Gillies RJ
J Cell Physiol; 1998 Jul; 176(1):196-205. PubMed ID: 9618159
[TBL] [Abstract][Full Text] [Related]
11. Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential.
Wei W; Jia G; von Tengg-Kobligk H; Heverhagen JT; Abdel-Rahman M; Wei L; Christoforidis JB; Davidorf F; Knopp MV
J Comput Assist Tomogr; 2017; 41(5):823-827. PubMed ID: 28448404
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts.
Ovrebø KM; Ellingsen C; Galappathi K; Rofstad EK
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e121-7. PubMed ID: 22381901
[TBL] [Abstract][Full Text] [Related]
13. Optical Redox Imaging of Lonidamine Treatment Response of Melanoma Cells and Xenografts.
Xu HN; Feng M; Nath K; Nelson D; Roman J; Zhao H; Lin Z; Glickson J; Li LZ
Mol Imaging Biol; 2019 Jun; 21(3):426-435. PubMed ID: 30151646
[TBL] [Abstract][Full Text] [Related]
14. Characterizing prostate tumor mouse xenografts with CEST and MT-MRI and redox scanning.
Cai K; Xu HN; Singh A; Haris M; Reddy R; Li LZ
Adv Exp Med Biol; 2013; 765():39-45. PubMed ID: 22879012
[TBL] [Abstract][Full Text] [Related]
15. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
[TBL] [Abstract][Full Text] [Related]
16. Assessment of tumor radioresponsiveness and metastatic potential by dynamic contrast-enhanced magnetic resonance imaging.
Øvrebø KM; Gulliksrud K; Mathiesen B; Rofstad EK
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):255-61. PubMed ID: 21816291
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced magnetic resonance imaging of tumors: preclinical validation of parametric images.
Egeland TA; Simonsen TG; Gaustad JV; Gulliksrud K; Ellingsen C; Rofstad EK
Radiat Res; 2009 Sep; 172(3):339-47. PubMed ID: 19708783
[TBL] [Abstract][Full Text] [Related]
18. The metastasis suppressor KISS1 lacks antimetastatic activity in the C8161.9 xenograft model of melanoma.
Navenot JM; Evans B; Oishi S; Setsuda S; Fujii N; Peiper SC
Melanoma Res; 2012 Apr; 22(2):140-50. PubMed ID: 22395416
[TBL] [Abstract][Full Text] [Related]
19. SOX9 is a dose-dependent metastatic fate determinant in melanoma.
Yang X; Liang R; Liu C; Liu JA; Cheung MPL; Liu X; Man OY; Guan XY; Lung HL; Cheung M
J Exp Clin Cancer Res; 2019 Jan; 38(1):17. PubMed ID: 30642390
[TBL] [Abstract][Full Text] [Related]
20. In vivo metabolic evaluation of breast tumor mouse xenografts for predicting aggressiveness using the hyperpolarized (13)C-NMR technique.
Xu HN; Kadlececk S; Pullinger B; Profka H; Cai K; Hariharan H; Rizi R; Li LZ
Adv Exp Med Biol; 2013; 789():237-242. PubMed ID: 23852500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
